Most CBD Pet Products Are About to Become Illegal

Most CBD pet products currently on the market will not survive the regulatory framework arriving in November 2026. This is not speculation. It is arithmetic.

Section 781 of the FDA Modernization Act directs the FDA to establish a regulatory pathway for cannabidiol products intended for animals. That pathway includes THC limits. And the expected threshold of 0.4 mg total THC per container is so low that the vast majority of full-spectrum CBD pet products on shelves today cannot meet it without complete reformulation.

We estimate that roughly 95% of current full-spectrum CBD pet products would fail the expected standard. Not because they are dangerous. Not because they are poorly made. But because the math of full-spectrum extraction and the new per-container THC limit are fundamentally incompatible at current formulations.

Here is what the regulation actually says, why the math eliminates most products, which product types survive, and what you should do about it.

What Section 781 of the FDA Modernization Act Actually Says

Section 781 was signed into law as part of the FDA reauthorization package. It directs the FDA to establish a regulatory framework specifically for CBD products intended for animal use, with a deadline of November 2026.

This is a significant distinction from the current legal situation. Since the 2018 Farm Bill legalized hemp-derived products containing less than 0.3% THC by dry weight, CBD pet products have existed in a regulatory gray zone. They are technically legal to produce from hemp, but the FDA has never established specific rules for their manufacture, labeling, or sale as animal products. Section 781 closes that gap.

What Section 781 does:

• Directs the FDA to create a formal regulatory pathway for animal CBD products
• Sets a November 2026 deadline for that framework to be established
• Opens the door for standardized manufacturing, testing, and labeling requirements
• Creates a mechanism for enforcement against non-compliant products

What Section 781 does not do:

• Ban CBD for pets outright
• Make it illegal to give your pet CBD
• Prohibit any specific type of CBD product by name

The regulation is not a ban. It is the creation of legal rules. But within those rules, one specific standard threatens to reshape the entire market: the THC threshold.

The THC Math That Eliminates Most Products

The 2018 Farm Bill set the legal THC limit for hemp at 0.3% by dry weight. That percentage-based standard applies to the raw plant material and has governed the industry for years. Most CBD pet product manufacturers consider themselves compliant if their source hemp is below 0.3% THC.

The expected FDA framework introduces a different measurement: total THC per container, not percentage by weight. And the anticipated threshold is 0.4 mg total THC per container.

This changes everything. Here is why.

Example 1: Full-Spectrum CBD Oil (30 mL Bottle)

A standard 30 mL bottle of full-spectrum CBD oil at 1,000 mg total CBD. At 0.3% THC by weight (the current legal maximum), that bottle contains approximately 3 mg of total THC.

The expected limit is 0.4 mg per container.

That product exceeds the threshold by 7.5 times.

Example 2: Higher-Potency CBD Oil (30 mL Bottle)

A 30 mL bottle at 3,000 mg total CBD, a common concentration for large-breed dogs. At 0.3% THC, the total THC in that bottle reaches approximately 9 mg.

That product exceeds the threshold by 22.5 times.

Example 3: Full-Spectrum CBD Treats (Bag of 30)

A bag of 30 full-spectrum CBD dog treats at 10 mg CBD per treat (300 mg total CBD per bag). Even with trace THC well below 0.3%, the total per-container THC easily exceeds 0.4 mg.

Which Products Survive

Not all CBD products are affected equally. The type of extract determines whether a product can meet the expected threshold.

CBD Isolate Products: Automatically Compliant

CBD isolate is pure cannabidiol (99%+ CBD) with all other cannabinoids removed, including THC. Isolate-based products contain zero THC by definition and would pass the 0.4 mg threshold without any reformulation.

The tradeoff: isolate products lack the other cannabinoids and terpenes present in whole-plant extracts. Proponents of the "entourage effect" argue that these additional compounds enhance CBD's therapeutic value. The clinical evidence for the entourage effect in veterinary medicine is limited, but some pet owners and veterinarians report better outcomes with whole-plant formulations.

Broad-Spectrum Products: Should Comply

Broad-spectrum CBD retains most cannabinoids and terpenes from the original plant but has the THC specifically removed. In theory, these products should contain zero THC and would be compliant.

In practice, "THC-free" and "below the limit of detection" are different things. Some broad-spectrum products contain trace THC that current labeling rounds to zero. Under a strict 0.4 mg per-container standard, even trace residual THC in a large-volume product could become a compliance issue. Brands using broad-spectrum extracts will need rigorous third-party testing to confirm true zero-THC status. Understanding the difference between CBD oil and hemp oil is already critical for label verification, and it will become even more important under the new framework.

Full-Spectrum Products: Reformulate or Exit

Full-spectrum products retain the complete cannabinoid profile of the hemp plant, including THC at or below 0.3%. As the math above demonstrates, most full-spectrum products cannot meet a 0.4 mg total-THC-per-container limit at standard CBD concentrations.

Some niche scenarios may survive: very low-potency full-spectrum products with small container sizes could potentially stay under the threshold. But the majority of commercial full-spectrum CBD pet products would need to either reformulate to remove THC (becoming broad-spectrum) or exit the market.

What This Means for CBD Pet Brands

The expected regulatory framework creates distinct categories of market impact.

Brands Already Selling Isolate or Broad-Spectrum: Positioned Well

Companies that already formulate with CBD isolate or verified broad-spectrum extract have the least disruption ahead. Their products should meet the THC threshold without changes. The main requirement will be updated labeling and third-party testing documentation to demonstrate compliance under the new framework.

Brands Selling Full-Spectrum Products: Reformulation Required

This is the majority of the market. Full-spectrum has been the dominant product type in pet CBD, marketed on the entourage effect and "whole-plant" benefits. These brands face a choice: invest in reformulation to remove THC (effectively becoming broad-spectrum), reduce product potency to stay under the per-container threshold, or discontinue their full-spectrum lines.

Reformulation is not trivial. It requires retooling extraction processes, sourcing new raw materials or adding THC-removal steps, reformulating and stability-testing every SKU, updating all labels and marketing materials, and obtaining new COAs for every batch. For smaller brands, the capital and timeline pressure may be prohibitive.

Amazon "Hemp" Products: Outside the Framework Entirely

Amazon prohibits the sale of CBD on its platform. Products marketed as "hemp oil" or "hemp extract" on Amazon are not CBD products, or at least, they are not supposed to be. These products exist outside the regulatory framework because they are not (officially) cannabidiol products at all. For a deeper look at what these products actually contain, see our hemp oil for dogs guide.

The regulatory framework may actually benefit legitimate CBD brands by creating a clearer legal distinction between real CBD products (regulated, tested, labeled) and the pseudo-CBD products that currently crowd the Amazon marketplace.

What This Means for Pet Parents

If you are currently giving your pet CBD, here is the practical guidance.

Do not panic. Your current product is not illegal. The regulatory framework has not been finalized, and enforcement is expected to begin in 2027 with a grace period. Nothing changes for you today.

Start checking COAs for total THC per container. Most COAs report THC as a percentage or as mg/mL. You need to calculate the total THC in the entire container. Multiply the per-mL THC concentration by the total volume. If the result is above 0.4 mg, that product will likely need to change under the new rules. Our CBD dosage guide walks through how to read COA documents.

Consider broad-spectrum or isolate products. If you want to future-proof your pet's CBD supply, broad-spectrum and isolate products are the safest bet for regulatory compliance. Many pets respond well to THC-free formulations. See our best CBD treats for dogs and best CBD oil for cats guides for COA-verified product picks. For the full regulatory timeline, state-by-state picture, and how Section 781 affects veterinarians and brands, see our complete Section 781 regulatory guide.

Watch for reformulation announcements. Reputable brands will likely begin announcing reformulation plans in the coming months. Brands that are transparent about their transition strategy are the ones worth continuing to buy from.

Products without COAs are unverifiable. This has always been true, but it becomes even more critical under a regulatory framework. If a product does not provide a current, batch-specific, third-party COA, you have no way to know what it contains, and neither does the FDA. Avoid these products regardless of the regulatory timeline.

If you are concerned about THC exposure or overdose risk, the upcoming regulation is actually designed to reduce that risk by setting enforceable limits. For dogs already taking CBD in treat form, our guides to CBD chews for dogs and CBD dog treats explain what to look for on labels.

The Bigger Picture: Why Regulation Is Actually Good

This may seem counterintuitive in an article about products becoming non-compliant. But the current state of the pet CBD market is not serving pet owners well.

Leafreport's 2020 analysis found that 56% of CBD pet products have inaccurate labels. More than half the products on the market do not contain what they claim. Some contain less CBD than advertised. Some contain more THC than listed. Some contain neither in the amounts stated.

No federal manufacturing standards govern pet CBD today. No required testing protocols. No standardized labeling. No enforcement mechanism for mislabeled products. The market is essentially self-regulated, and as the 56% mislabeling rate demonstrates, self-regulation is not working.

A formal FDA regulatory framework would establish:

• Standardized manufacturing practices (cGMP requirements)
• Mandatory third-party testing with specific analytes
• Accurate labeling requirements with enforceable consequences
• Clear THC limits that protect THC-sensitive species (dogs are significantly more sensitive to THC than humans)
• A legal mechanism to remove non-compliant or dangerous products from the market

The short-term disruption is real. Products will disappear. Brands will close. Prices may increase as reformulation costs are passed through. But the products that survive will be verified, standardized, and trustworthy, which is not something you can say about the current market.

This parallels what happened when the dietary supplement industry faced FDA oversight under the Dietary Supplement Health and Education Act. Painful in the short term. Better for consumers in the long term.

Our editorial standards page explains why we already apply the kind of verification that regulation will eventually require across the industry.

Timeline: What Happens Next

Now Through November 2026

The FDA is finalizing the regulatory framework. Industry comment periods and stakeholder consultations are ongoing. Brands that are paying attention are already beginning to assess their product lines for compliance. No enforcement action is happening yet.

November 2026: Regulatory Deadline

Section 781 directs the FDA to have a framework established by this date. This does not mean enforcement begins immediately on November 1. It means the rules should be defined and published. There may be delays. The FDA frequently misses Congressional deadlines.

2027: Expected Enforcement Begins

Following publication of the final framework, the FDA will likely provide a compliance grace period for manufacturers to reformulate, relabel, and retest products. The length of this grace period has not been announced. Based on precedent with similar regulatory frameworks, 6–12 months is a reasonable expectation.

What to Watch

• FDA.gov announcements on animal CBD regulatory proceedings
• Federal Register notices related to Section 781 implementation
• Brand communications about product reformulation
• Changes to product labels (switching from "full-spectrum" to "broad-spectrum")
• Industry trade group statements from organizations like the National Animal Supplement Council (NASC)

Frequently Asked Questions

Is CBD for pets becoming illegal?

CBD itself is not becoming illegal. Section 781 of the FDA Modernization Act directs the FDA to create a regulatory framework for animal CBD products by November 2026. That framework is expected to include strict THC limits (0.4 mg total THC per container) that would make most current full-spectrum products non-compliant. Broad-spectrum and isolate CBD products with zero THC would remain legal under the expected rules.

When does the new CBD pet regulation take effect?

Section 781 directs the FDA to establish a regulatory framework for animal CBD by November 2026. Enforcement is expected to follow in 2027, likely with a grace period for manufacturers to reformulate and relabel. The FDA has not yet published a final rule, so exact enforcement dates may shift.

Will my current CBD product still be available?

It depends on the product type. CBD isolate and broad-spectrum products (zero THC) should remain available and compliant. Full-spectrum products that contain any measurable THC will likely need to be reformulated to meet the expected 0.4 mg total THC per container threshold. Some brands may discontinue full-spectrum lines rather than reformulate. Check your product's COA for total THC content per container, not just the percentage.

Should I switch to a THC-free CBD product now?

There is no urgency to switch today since the regulatory framework is not yet finalized. However, if your pet does well on broad-spectrum or isolate CBD, those products will not be affected by the upcoming THC restrictions. If you currently use full-spectrum CBD, consider a gradual transition to broad-spectrum while monitoring for any changes in effectiveness. The clinical evidence for the entourage effect in pets is limited, and many pets respond well to THC-free formulations.